CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 41 enrolled
Drug / intervention
Jatenzodrug
Likely dose
Jatenzo 237 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04983940
NCT04983940Phase 4Completed
CompareCT.gov

Patient Satisfaction After Switching to Oral Testosterone Undecanoate in Men Currently on Testosterone Therapy

University of Miami·interventional·Posted Jul 30, 2021·Updated Dec 14, 2023

In Brief

A Phase 4 clinical trial evaluating Jatenzo for Testosterone Deficiency. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The purpose of this research study is to evaluate patient satisfaction with an oral testosterone agent, Jatenzo, compared to other forms of testosterone therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTestosterone Deficiency
CountriesUnited States
CollaboratorsClarus Therapeutics, Inc.

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedJul 30, 2021
Enrollment StartJun 18, 2021
Primary CompletionApr 6, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.9 years ago

Interventions

Jatenzodrug

237 mg soft gel capsule taken twice a day by mouth with food.